Efficient suppression of FGF-2-induced ERK activation by the cooperative interaction among mammalian Sprouty isoforms

Journal of Cell Science

Volumn 118, Issue 24, 2005, Pages 5861-5871

  Ozaki, Kei Ichi ^a   Miyazaki, Satsuki ^a   Tanimura, Susumu ^a   Kohno, Michiaki ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

ERK pathway; FGF; Negative feedback inhibition; Receptor tyrosine kinase; Sprouty

Indexed keywords

CELL PROTEIN; FIBROBLAST GROWTH FACTOR 2; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN INHIBITOR; SOS PROTEIN; SPROUTY PROTEIN; SPROUTY1 PROTEIN; SPROUTY2 PROTEIN; SPROUTY3 PROTEIN; SPROUTY4 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; INHIBITION KINETICS; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLAST GROWTH FACTOR 2; GRB2 ADAPTOR PROTEIN; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; PROTEIN BINDING; PROTEIN ISOFORMS; RECEPTOR PROTEIN-TYROSINE KINASES; SOS1 PROTEIN; SWISS 3T3 CELLS;

ANIMALIA; MAMMALIA;

EID: 30644457873     PISSN: 00219533     EISSN: None     Source Type: Journal    
DOI: 10.1242/jcs.02711     Document Type: Article

References (47)

1. Blume-Jensen, P. and Hunter, T. (2001). Oncogenic kinase signaling. Nature 411, 355-365.
2. Camps, M., Nichols, A. and Arkinstall, S. (1999). Dual specificity phosphatases: a gene family for control of MAP kinase function. FASEB J. 14, 6-16.
3. Casci, T., Vinos, J. and Freeman, M. (1999). Sprouty, an intracellular inhibitor of Ras signaling. Cell 96, 655-665.
4. Christofori, G. (2003). Split personalities: the agonistic antagonist Sprouty. Nat. Cell Biol. 5, 377-379.
5. Egan, J. E., Hall, A. B., Yatsula, B. A. and Bar-Sagi, D. (2002). The bimodal regulation of epidermal growth factor signaling by human Sprouty proteins. Proc. Natl. Acad. Sci. USA 99, 6041-6046.
6. Farooq, A. and Zhou, M. M. (2004). Structure and regulation of MAPK phosphatases. Cell Signal. 16, 769-779.
7. Gross, I., Bassit, B., Benezra, M. and Licht, J. D. (2001). Mammalian sprouty proteins inhibit cell growth and differentiation by preventing ras activation. J. Biol. Chem. 276, 46460-46468.
8. Gum, J. R. J. (1992). Mucin genes and the proteins they encode: structure, diversity, and regulation. Am. J. Respir. Cell Mol. Biol. 7, 557-564.
9. Hacohen, N., Kramer, S., Sutherland, D., Hiromi, Y. and Krasnow, M. A. (1998). sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. Cell 92, 253-263.
10. Hadari, Y. R., Kouhara, H., Lax, I. and Schlessinger, J. (1998). Binding of Shp2 tyrosine phosphatase to FRS2 is essential for fibroblast growth factor-induced PC12 cell differentiation. Mol. Cell. Biol. 18, 3966-3973.
11. Hall, A. B., Jura, N., DaSilva, J., Jang, Y. J., Gong, D. and Bar-Sagi, D. (2003). hSpry2 is targeted to the ubiquitin-dependent proteasome pathway by c-Cbl. Curr. Biol. 13, 308-314.
12. Hanafusa, H., Torii, S., Yasunaga, T. and Nishida, E. (2002). Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signaling pathway. Nat. Cell Biol. 4, 850-858.
13. Hanafusa, H., Torii, S., Yasunaga, T., Matsumoto, K. and Nishida, E. (2004). Shp2, an SH2-containing protein-tyrosine phosphatase, positively regulates receptor tyrosine kinase signaling by dephosphorylating and inactivating the inhibitor Sprouty. J. Biol. Chem. 279, 22992-22995.
14. Hanahan, D. and Weinberg, R. A. (2000). The hallmarks of cancer. Cell 100, 57-70.
15. Hoshino, R., Chatani, Y., Yamori, T., Tsuruo, T., Oka, H., Yoshida, O., Shimada, Y., Ari-I, S., Wada, H., Fujimoto, J. et al. (1999). Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18, 813-822.
16. Kip1. J. Biol. Chem. 276, 2686-2692.
17. Hunter, T. (2000). Signaling-2000 and beyond. Cell 100, 113-127.
18. Impagnatiello, M. A., Weitzer, S., Gannon, G., Compagni, A., Cotton, M. and Christofori, G. (2001). Mammalian sprouty-1 and -2 are membrane-anchored phosphoprotein inhibitors of growth factor signaling in endothelial cells. J. Cell Biol. 152, 1087-1098.
19. Iwasaki, S., Iguchi, M., Watanabe, K., Hoshino, R., Tsujimoto, M. and Kohno, M. (1999). Specific activation of the p38 mitogen-activated protein kinase signaling pathway and induction of neurite outgrowth in PC12 cells by bone morphogenetic protein-2. J. Biol. Chem. 274, 26503-26510.
20. Kohno, M. and Pouyssegur, J. (2003). Pharmacological inhibitors of the ERK signaling pathway: application as anticancer drugs. Prog. Cell Cycle Res. 5, 219-224.
21. Kouhara, H., Hadari, Y. R., Spivak-Kroizman, T., Schilling, J., Bar-Sagi, D., Lax, I. and Schlessinger, J. (1997). A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. Cell 89, 693-702.
22. Kramer, S., Okabe, M., Hacohen, N., Krasnow, M. A. and Hiromi, Y. (1999). Sprouty: a common antagonist of FGF and EGF signaling pathways in Drosophila. Development 126, 2515-2525.
23. ras activation. J. Biol. Chem. 270, 25320-25323.
24. Lee, S. H., Schloss, D. J., Jarvis, L., Krasnow, M. A. and Swain, J. L. (2001). Inhibition of angiogenesis by a mouse sprouty protein. J. Biol. Chem. 276, 4128-4133.
25. Li, N., Batzer, A., Daly, R., Yajnik, V., Skolnik, E., Chardin, P., Bar-Sagi, D., Margolis, B. and Schlessinger, J. (1993). Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling. Nature 363, 85-88.
26. Minowada, G., Jarvis, L. A., Chi, C. L., Neubuser, A., Sun, X., Hacohen, N., Krasnow, M. A. and Martin, G. R. (1999). Vertebrate Sprouty genes are induced by FGF signaling and can cause chondrodysplasia when overexpressed. Development 126, 4465-4475.
27. Oka, H., Chatani, Y., Hoshino, R., Ogawa, O., Kakehi, Y., Terachi, T., Okada, Y., Kawaichi, M., Kohno, M. and Yoshida, O. (1995). Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res. 55, 4182-4187.
28. Ozaki, K., Kadomoto, R., Asato, K., Tanimura, S., Itoh, N. and Kohno, M. (2001). ERK pathway positively regulates the expression of Sprouty genes. Biochem. Biophys. Res. Commun. 285, 1084-1088.
29. Reich, A., Sapir, A. and Shilo, B. (1999). Sprouty is a general inhibitor of receptor tyrosine kinase signaling. Development 126, 4139-4147.
30. Rozakis-Adcock, M., Fernley, R., Wade, J., Pawson, T. and Bowtell, D. (1993). The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1. Nature 363, 83-85.
31. Sasaki, A., Taketomi, T., Wakioka, T., Kato, R. and Yoshimura, A. (2001). Identification of a dominant negative mutant of Sprouty that potentiates fibroblast growth factor-but not epidermal growth factor-induced ERK activation. J. Biol. Chem. 276, 36804-36808.
32. Sasaki, A., Taketomi, T., Kato, R., Saeki, K., Nonami, A., Sasaki, M., Kuriyama, M., Saito, N., Shibuya, M. and Yoshimura, A. (2003). Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to Raf1. Nat. Cell Biol. 5, 427-432.
33. Schlessinger, J. (2000). Cell signaling by receptor tyrosine kinase. Cell 103, 211-225.
34. Simon, M. A. (2000). Receptor tyrosine kinases: specific outcomes from general signals. Cell 103, 13-15.
35. Tanimura, S., Nomura, K., Ozaki, K., Tsujimoto, M., Kondo, T. and Kohno, M. (2002). Prolonged nuclear retention of activated extracellular signal-regulated kinase 1/2 is required for hepatocyte growth factor-induced cell motility. J. Biol. Chem. 277, 28256-28264.
36. Tanimura, S., Asato, K., Fujishiro, S. and Kohno, M. (2003). Specific blockade of the ERK pathway inhibits the invasiveness of tumor cells: down-regulation of matrix metalloproteinase-3/-9/-14 and CD44. Biochem. Biophys. Res. Commun. 304, 801-806.
37. Tefft, J. D., Lee, M., Smith, S., Leinwand, M., Zhao, J., Bringas, P. J., Crowe, D. L. and Warburton, D. (1999). Conserved function of mSpry-2, a murine homolog of Drosophila sprouty, which negatively modulates respiratory organogenesis. Curr. Biol. 9, 219-222.
38. Tefft, J. D., Lee, M., Smith, S., Crowe, D. L., Bellusci, S. and Warburton, D. (2002). mSprouty2 inhibits FGF10-activated MAP kinase by differentially binding to upstream target proteins. Am. J. Physiol. Lung Cell Mol. Physiol. 283, L700-L706.
39. Voas, M. G. and Rebay, I. (2004). Signal integration during development: insights from the Drosophila eye. Dev. Dyn. 229, 162-175.
40. Wallis, R. and Drickamer, K. (1999). Molecular determinants of oligomer formation and complement fixation in mannose-binding proteins. J. Biol. Chem. 274, 3580-3589.
41. Wennstrom, S. and Downward, J. (1999). Role of phosphoinositide 3-kinase in activation of ras and mitogen-activated protein kinase by epidermal growth factor. Mol. Cell. Biol. 19, 4279-4288.
42. Wong, E. S., Lim, J., Low, B. C., Chen, Q. and Guy, G. R. (2001). Evidence for direct interaction between Sprouty and Cbl. J. Biol. Chem. 276, 5866-5875.
43. Wong, E. S., Fong, C. W., Lim, J., Yusoff, P., Low, B. C., Langdon, W. Y. and Guy, G. R. (2002). Sprouty2 attenuates epidermal growth factor receptor ubiquitylation and endocytosis, and consequently enhances Ras/ERK signalling. EMBO J. 21, 4796-4808.
44. Yigzaw, Y., Cartin, L., Pierre, S., Scholich, K. and Patel, T. B. (2001). The C terminus of sprouty is important for modulation of cellular migration and proliferation. J. Biol. Chem. 276, 22742-22747.
45. Yigzaw, Y., Poppleton, H. M., Sreejayan, N., Hassid, A. and Patel, T. B. (2003). Protein-tyrosine phosphatases-1B (PTP1B) mediates the anti-migratory actions of Sprouty. J. Biol. Chem. 278, 284-288.
46. Yusoff, P., Lao, D. H., Ong, S. H., Wong, E. S., Lim, J., Lo, T. L., Leong, H. F., Fong, C. W. and Guy, G.R. (2002). Sprouty2 inhibits the Ras/MAP kinase pathway by inhibiting the activation of Raf. J. Biol. Chem. 277, 3195-3201.
47. Zwick, E., Bange, J. and Ullrich, A. (2002). Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol. Med. 8, 17-23.